Analytical characterization of viral vectors: key challenges and strategies

Viral vector analytical characterization has become a critical aspect of gene therapy development. With the increasing complexity of advanced therapy medicinal products (ATMPs), expectations around analytical strategies, product understanding, and control have significantly evolved.

Viral vectors sit at the center of today's gene therapy pipeline, functioning as both delivery systems and therapeutics. They are one of the most important delivery platforms within advanced therapy medicinal products (ATMPs), The molecular complexity and inherent variability of viral vectors create a level of analytical complexity that differs from that seen with more established biologics. If you have already looked at the broader challenges covered in biotherapeutics analytical testing, viral vectors make many of those issues more pronounced: biological variability, product heterogeneity, method sensitivity, and the need to connect analytics to product performance. That is exactly why viral vector analytical testing has become such a critical part of their CMC strategy, from early development through release and stability. For development teams, the challenge is not simply generating data. It is about building a characterization package that clearly explains what the vector is (identity), how consistent it is (reliability), how clean it is (purity), and whether it performs the intended biological function (potency)¹.

Biological variability of final viral product

One major factor is biological variability. As viral vectors are produced inside living systems, the harvest product is shaped by upstream conditions, cell line choice and overall well-being, transfection efficiency, harvest timing, purification performance, and storage history. Even when the process is well controlled, final product can still vary from batch to batch. Shifts in viral particles properties such empty and full capsid distribution, aggregation behavior, infectivity, and genome integrity can all change effectiveness of the viral product.

Impurity profiling of viral batches

Next to mapping of biological variability, impurity profiling is also considered key. Viral vector preparations can contain host cell proteins, residual host cell DNA, plasmid-derived material, helper-virus related species, and process-related residues. These are not minor concerns. They affect product quality, safety assessment, and process understanding.

Genome integrity of the vector

Genome integrity adds another layer of complexity. A vector may contain the intended sequence, but that does not necessarily mean that the packaged genome is complete, correctly oriented, or intact across the population. Truncations, rearrangements, and packaging heterogeneity can have direct implications for performance.

Potency

Potency is where chemistry, biology, and assay design all meet. Potency is the quantitative measure of a viral product’s biological activity, rather than particle count, confirming its efficacy and consistency. A vector can have a measurable titter and still underperform functionally. That is why gene therapy analytical testing cannot stop counting particles or genomes. It also has to address biological activity in a meaningful way^2,3,4.

Genome integrity and identity

Identity is considered the starting point. Teams need to confirm the correct viral vector construct, including genetic payload. For viral vectors, identity often extends beyond a simple yes-or-no answer. It also includes genome structure, integrity, and the ratio of expected versus unexpected genome forms. Genome integrity is particularly challenging in viral vector characterization, with populations often containing intact, truncated, and rearranged genome species. This genomic heterogeneity is not obvious from a basic titer readout⁵. Capsid heterogeneity adds a further layer of complexity, as viral vector preparations often include a mixture of full, empty, and partially filled particles, ultimately influencing titer measurements and making it difficult to accurately define and measure the true product. Genome integrity becomes especially important when packaging limits are being pushed or when sequence elements create a higher risk of truncation or rearrangement.

Potency and infectivity

Potency is a key attribute in gene therapy, telling you how well the vector produces a measurable biological response, including intracellular trafficking, transgene expression and measurable functional response. Infectivity is closely related but not identical. Infectivity describes the vector’s ability to enter cells and initiate transduction, contributing to overall activity. A vector may bind and enter cells, yet still fail to deliver effective biological activity. Both measures can be relevant, depending on the vector system and clinical mechanism of action. For gene therapy products, this usually involves a combination of cell entry, intracellular trafficking, transgene expression, and a measurable functional response. This is often assessed through cell-based assays measuring transduction efficiency or gene expression, that contribute to potency.

Purity and impurities

Purity is never just about one contaminant. Viral vector products can contain product-related impurities such as empty capsids, aggregates, and variant populations, along with process-related contaminants like host cell proteins, host cell DNA, detergents, and residual solvents. Each impurity class tells a different story. Some reflect upstream production behavior. Others point to purification performance or formulation compatibility.

Quantification of viral genomes techniques (Titer determination)

Quantitative PCR (qPCR) is still one of the go-to methods for measuring the concentration of packaged viral vector genome to determine viral titer. Most teams are familiar with it, it is quick to run, and it works well when the assay is set up carefully. At the same time, it can be quite sensitive to primer design and sample handling. Digital droplet (ddPCR) offers an alternative approach, providing a more absolute quantification that helps cut down some of the variability that comes with calibration curves. Calibration curves link known concentrations to a signal, but can introduce variability as the relationship may vary between runs, assays, or standards. While PCR-based methods measure the genome directly, ELISA and IEX can provide an additional layer of viral product titer understanding. For instance, with AAV products, ELISA for capsid quantification provides insight into capsid-related content, making it a useful complement to genome-based methods. on capsid variants and charge heterogeneity. For instance, with AAV products, ELISA for capsid quantification provides insight into capsid-related content, making it a useful complement to genome-based methods. IEX chromatography can also support titer determination, particularly when capsid charge variants and other heterogeneous capsid populations are present.

Purity and impurities

On the impurity side, host cell DNA and host cell proteins remain key analytical targets. Host cell protein testing is often determined using ELISA-based assays, while residual DNA analysis may rely on nucleic acid-based methods, particularly quantitative PCR (qPCR) or real-time PCR. For process-related impurities, residual detergents and organic solvents are usually better addressed using mass spectrometry and chromatography-based methods. These approaches can detect and quantify low-level process residues that are highly relevant to release and comparability work⁷.

Identity & Genome integrity

For identity and genome integrity, NGS and ddPCR are increasingly useful because they can go beyond basic confirmation and help describe the packaged genome population in more detail. NGS can provide sequence-level insight and reveal forms of heterogeneity that would be easy to miss with simpler assays. Mass spectrometry also has an important place in structural characterization. It can support analysis of capsid composition and post-translational modifications (PTMs) where these are relevant to the product and production system⁸.

Potency assays

For most gene therapy programs, the core approach is an in vitro cell-based assay that reflects a meaningful aspect of biological activity. That may involve transduction, transgene expression, reporter activity, or another relevant functional endpoint. The key is relevance. A good potency assay should connect to the mechanism of action in a way that can be reliably implemented for development and quality control.

Key analytical challenges in practice

On paper, a method can look robust. In the lab, things get more complicated.

Batch-to batch variability in viral titer and quality remains one of the most significant and persistent challenges in viral vector manufacturing. Even when manufacturing parameters are controlled, biologically based production systems are inherently sensitive to small changes in their environment. These systems rely on living cells whose productivity is sensitive to subtle differences in culture conditions, that can influence viral titer, impurity levels, infectivity, and potency across batches. The analytical methods must be sufficiently sensitive and robust to distinguish normal biological variation from meaningful shifts in product quality.

Assay variability, especially in cell-based assays, is another real issue. Cell state, passage number, media conditions, reagent lots, and incubation timing can all affect results. Potency and infectivity assays are often the most sensitive in this context, as they mirror functional performance. That is why, in biologics and viral vector manufacturing, assay controls, system suitability, training, and method lifecycle thinking matter so much for consistent, reliable results. This is especially important because methods like potency, infectivity, and titer determination assays can change in performance over time or become less aligned with shifts in product and process development

And then there is also the ongoing issue of a lack of standardization across the field. Different organizations may measure similar attributes in different ways or use different reference materials. That makes technology transfer, comparability, and cross-program benchmarking harder than many teams expect⁹.

Regulatory expectations for gene therapy products

Regulators expect a characterization strategy that matches the complexity of the product. For gene therapy developers working under FDA and EMA frameworks, that means demonstrating control over identity, strength, quality, purity, and potency using methods appropriate for the development stage. Within the ATMP framework, viral vectors are treated as high-complexity biological products. Agencies generally want to see that the chosen ATMP analytical methods are scientifically sound, relevant to product quality, and capable of supporting process development, release, stability, and comparability. Teams that need broader support across release and characterization often look for specialized biologics characterization services that can align method selection with both product science and regulatory expectations. And that’s where we come in. As an analytical extension of your team, we offer the analytical and technical know-how to streamline your product release. From identity and purity to potency, our testing methods ensure you meet every ICH guideline with confidence.

Frequently asked questions on viral vector analytics

How are viral vectors characterized?

Viral vectors are characterized through an orthogonal set of methods that examine identity, genome integrity, titer, purity, impurities, infectivity, and potency. No single assay is sufficient on its own.

What defines potency in gene therapy?

Potency in gene therapy is defined by the vector's ability to produce the intended biological effect. In practice, that often means using a cell-based assay to measure transduction and downstream functional activity.

What are key analytical challenges?

Biological variability from batch to batch is a real challenge. So is assay variability, especially with complex cell-based methods. And there is very little standardization across platforms and labs. All of that makes viral vector analytical testing genuinely challenging.

References

1. Cambridge Healthtech Institute. (2026). Cambridge Healthtech Institute's 11th annual gene therapy CMC & analytics: Improving quality, control, and CMC of genetic medicines and in vivo CAR Ts. Assessed from https://www.bioprocessingsummit.com/gene-therapy-cmc
2. Hagner McWhirter, Å. (2024, April 9). Tips for viral vector production. Cytiva Life Sciences. Assessed from https://www.cytivalifesciences.com/en/us/insights/tips-for-viral-vector-production
3. Wright, J. F. (2014). Product-related impurities in clinical-grade recombinant AAV vectors: Characterization and risk assessment. Biomedicines, 2(1), 80–97.
4. Blahetek, G., Lindner, B., Oti, M., Schön, C., & Strobel, B. (2025). AAV yield, bioactivity, and particle heterogeneity are impacted by genome size and non-coding DNA elements. Molecular Therapy Methods & Clinical Development, 33(3), 101499.
5. Kontogiannis, T., Braybrook, J., McElroy, C., Foy, C., Whale, A. S., Quaglia, M., & Smales, C. M. (2024). Characterization of AAV vectors: A review of analytical techniques and critical quality attributes. Molecular Therapy Methods & Clinical Development, 32(3), 101309.
6. Zhao, Y., Xia, Q., Yin, Y., & Wang, Z. (2016). Comparison of droplet digital PCR and quantitative PCR assays for quantitative detection of Xanthomonas citri subsp. citri. PLoS ONE, 11(7), e0159004.
7. Yao, Y., Wen, X., Pan, H., & Chen, Z. (2025). Residual host cell proteins: Sources, properties, detection methods and data acquisition modes. Frontiers in Microbiology, 16, 1658366.
8. Prantner, A., & Maar, D. (2023). Genome concentration, characterization, and integrity analysis of recombinant adeno-associated viral vectors using droplet digital PCR. PLoS ONE, 18(1), e0280242.
9. European Medicines Agency (EMA). (2022). Concept paper on the development and data requirements of potency tests for cell-based therapy products and the relation to clinical efficacy. Assessed from https://www.ema.europa.eu/en/documents/scientific-guideline/concept-paper-development-and-data-requirements-potency-tests-cell-based-therapy-products-and-relation-clinical-efficacy_en.pdf